Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Identification of Rare Mutation May Lead to Heart Repair Gene Therapy

By BiotechDaily International staff writers
Posted on 17 Mar 2014
Image: In the heart muscle cell above, the arrows show an early sign of replication (Photo courtesy of Johns Hopkins University).
Image: In the heart muscle cell above, the arrows show an early sign of replication (Photo courtesy of Johns Hopkins University).
Identification of the mutation responsible for an exceedingly rare type of heart defect in infants may pave the way for a gene therapy approach for regenerating adult heart tissue damaged by heart attack or disease.

Investigators at Johns Hopkins University (Baltimore, MD, USA) had been examining the hearts removed from two infant siblings during heart transplant surgery. Initial findings were that cells in the heart muscle (cardiomyocytes) were continuing to divide despite the fact that the infants had passed the age by which such cell division has normally terminated. The investigators established that the infants' genomes contained two abnormal copies of the ALMS1 gene. The same mutation was then found in five infant patients, including two sets of siblings, at the Hospital for Sick Children (Toronto, Canada).

The investigators reported in the March 4, 2014, online edition of the journal Nature Communications that the ALMS1 gene mutation caused a deficiency of the Alström protein that impaired the ability of the heart cells to stop dividing. In a genetically engineered mouse model, animals that lacked the ALMS1 gene displayed increased cardiomyocyte proliferation at two weeks postnatal compared with wild-type littermates. Furthermore, cultured cardiomyocytes divided abnormally after exposure to siRNA (short interfering RNA) that blocked expression of the ALMS1 gene.

“This study offers hope that we can someday find a way to restore the ability of heart cells to divide in response to injury and to help patients recover from many kinds of cardiac dysfunction,” said senior author Dr. Daniel P. Judge, associate professor of cardiology at Johns Hopkins University. “Things usually heal up well in many parts of the body through cell division, except in the heart and the brain. Although other work has generated a lot of excitement about the possibility of treatment with stem cells, our research offers an entirely different direction to pursue in finding ways to repair a damaged heart.”

“The children who helped us recognize the importance of this gene were born with a rare condition that leads to heart failure and many other problems, such as diabetes, obesity, blindness, and deafness,” said Dr. Judge. “Now we hope to apply these discoveries to help millions of others with heart disease.”

Related Links:

Johns Hopkins University
The Hospital for Sick Children
 


comments powered by Disqus

Channels

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.